NCT06113679View on ClinicalTrials.gov

Pilot Randomized Study of RD-X19 Tx Device in Subjects With PCC (Long Covid) in the Outpatient Setting

NATerminatedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

October 30, 2023

Primary Completion Date

May 24, 2024

Study Completion Date

June 21, 2024

Conditions
Post COVID-19 Condition (PCC)
Interventions
DEVICE

RDX-19

RD-X19 device with a 5 minute, 32 J/cm2 dose, 2X/day, 7 days. Each treatment at least 6 hours apart.

Trial Locations (2)

14051

Site 2_WellNow Urgent Care and Research, East Amherst

38358

Site 1_Helios - Physician Quality Care, Milan

Sponsors

Collaborators (1)

NAMSA
All Listed Sponsors
collaborator

NAMSA

OTHER

lead

EmitBio Inc.

INDUSTRY

NCT06113679 - Pilot Randomized Study of RD-X19 Tx Device in Subjects With PCC (Long Covid) in the Outpatient Setting | Biotech Hunter | Biotech Hunter